GeoVax Labs (NASDAQ:GOVX) Shares Up 21.1% – Should You Buy?

GeoVax Labs Inc. (NASDAQ:GOVX) was up 21.1% on Friday . The company traded as high as $0.2105 and last traded at $0.2070. Approximately 6,520,937 shares changed hands during mid-day trading, an increase of 75% from the average daily volume of 3,732,439 shares. The stock had previously closed at $0.1710.

Wall Street Analyst Weigh In

A number of equities analysts have commented on GOVX shares. D. Boral Capital decreased their price target on GeoVax Labs from $9.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday, November 19th. Weiss Ratings reissued a “sell (e+)” rating on shares of GeoVax Labs in a research note on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.50.

GeoVax Labs Trading Up 21.1%

The firm has a market cap of $6.22 million, a PE ratio of -0.15 and a beta of 3.67. The firm has a fifty day simple moving average of $0.38 and a two-hundred day simple moving average of $0.59.

GeoVax Labs (NASDAQ:GOVX) last announced its earnings results on Thursday, November 13th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.07). GeoVax Labs had a negative net margin of 403.88% and a negative return on equity of 489.67%. Equities analysts expect that GeoVax Labs Inc. will post -4.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GeoVax Labs

Institutional investors and hedge funds have recently modified their holdings of the stock. Sabby Management LLC purchased a new stake in GeoVax Labs in the third quarter worth about $313,000. Armistice Capital LLC purchased a new position in shares of GeoVax Labs during the 3rd quarter worth approximately $253,000. Hudson Bay Capital Management LP bought a new position in shares of GeoVax Labs in the 3rd quarter worth approximately $47,000. Finally, Jane Street Group LLC bought a new position in shares of GeoVax Labs in the 1st quarter worth approximately $27,000. 6.09% of the stock is owned by hedge funds and other institutional investors.

GeoVax Labs Company Profile

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.